Prebiotics and probiotics; modifying and mining the microbiota

Pharmacological Research

Volumn 61, Issue 3, 2010, Pages 213-218

  Quigley, Eamonn M M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bifidobacteria; Diarrhea; Enteric infections; Inflammatory bowel disease; Intestinal flora; Irritable bowel syndrome; Lactobacilli; Microbiota; Prebiotics; Probiotics

Indexed keywords

PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; VSL3;

BACTERIAL GROWTH; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; GROWTH REGULATION; HEALTH STATUS; HUMAN; ILEITIS; IMMUNE SYSTEM; INFECTION; INTESTINE LYMPHATIC TISSUE; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; STREPTOCOCCUS THERMOPHILUS; ANIMAL; DIET THERAPY; DRUG EFFECTS; GASTROINTESTINAL DISEASE; INTESTINE MUCOSA; METAGENOME; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; GASTROINTESTINAL DISEASES; HUMANS; INTESTINAL MUCOSA; METAGENOME; PREBIOTICS; PROBIOTICS;

EID: 77649275204     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.01.004     Document Type: Review

References (75)

1. Palmer C., Bik E.M., DiGiulio D.B., Relman D.A., and Brown P.O. Development of the human infant intestinal microbiota. PloS Biol 5 (2007) 1556-1573
2. Guarner F., and Malagelada J.R. Gut flora in health and disease. Lancet 361 (2003) 512-519
3. Neish A.S. Microbes in gastrointestinal health and disease. Gastroenterology 136 (2009) 65-80
4. Hattori M., and Taylor T.D. The human intestinal microbiome: a new frontier of human biology. DNA Res 16 (2009) 1-12
5. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., et al. Diversity of the human intestinal microbial flora. Science 308 (2005) 1635-1638
6. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol 16 (2002) 915-931
7. O'Hara A.M., and Shanahan F. Gut microbiota: mining for therapeutic potential. Clin Gastroenterol Hepatol 5 (2007) 274-284
8. Isolauri E., Salminen S., and Ouwehand A.C. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 18 (2004) 299-313
9. Kelly C.P., and LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 359 (2008) 1932-1940
10. Neu J., Mshvildadze M., and Mai V. A roadmap for understanding and preventing necrotizing enterocolitis. Curr Gastroenterol Rep 10 (2008) 450-457
11. Quigley E.M.M., and Abu-Shanab A. The diagnosis of small intestinal bacterial overgrowth: the challenges persist!. Expert Rev Gastroenterol Hepatol 3 (2009) 77-87
12. Sartor R.B., and Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep 9 (2007) 497-507
13. Tilg H., Moschen A.R., and Kaser A. Obesity and the microbiota. Gastroenterology 136 (2009) 1476-1483
14. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., and Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006) 1027-1031
15. Zhang H., DiBaise J.K., Zuccolo A., Kudrna D., Braidotti M., Yu Y., et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA 106 (2009) 2365-2370
16. Shanahan F. Probiotics: a perspective on problems and pitfalls. Scand J Gastroenterol 38 Suppl. (2003) 34-36
17. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32006R1924R(01):EN:NOT Accessed January 6th 2010.
18. Kotarsky K., Sitnik K.M., Stenstad H., Kotarsky H., Schmidtchen, Koslowski M., et al. A novel role for constitutively expressed epithelial-derived chemokines as antibacterial peptides in the intestinal mucosa. Nat Immunol 3 (2010) 40-48
19. O'Mahony L., O'Callaghan L., McCarthy J., Shilling D., Scully P., Sibartie S., et al. Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. Am J Physiol Gastrointest Liver Physiol 290 (2006) G839-G845
20. O'Toole P.W., and Cooney J.C. Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdiscip Perpsect Infect Dis (2008) 10.1155/2008/175285
21. Bonetti A., Morelli L., and Campominos E. Assessment of the persistence in the human intestinal tract of two probiotic Lactobacilli Lactobacillus salivarius I 1794 and Lactobacillus paracasei I 1688. Microb Ecol Health Dis 4 (2002) 229-233
22. Engelbrektson A.L., Korzenik J.R., Sanders M.E., Clement B.G., Leyer G., Klaenhammer T.R., et al. Analysis of treatment effects on the microbial ecology of the human intestine. FEMS Microbiol Ecol 57 (2006) 239-250
23. Cronin M., Sleator R.D., Hill C., Fitzgerald G.F., and van Sinderen D. Development of a luciferase-based reporter system to monitor Bifidobacterium breve UCC2003 persistence in mice. BMC Microbiol 8 (2008) 161 10.1186/1471-2180-8-161
24. Hibbing M.E., Fuqua C., Parsek M.R., and Peterson S.B. Bacterial competition: surviving in the microbial jungle. Nature Rev Microbiol 8 (2010) 15-25
25. Preidis G.A., and Versalovic J. Targeting the human microbiome with antibiotics, probiotics and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136 (2009) 2015-2031
26. Zeng J., Li Y.Q., Zuo X.L., Zhen Y.B., Yang J., and Liu C.H. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 28 (2008) 994-1002
27. Pagnini C., Saeed R., Bamias G., Arseneau K.O., Pizarro T.T., and Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA (2009) December [Epub ahead of print]
28. Quigley E.M.M. Bacteria: a new player in gastrointestinal motility disorders-infections, bacterial overgrowth and probiotics. Gastroenterol Clin N Am 36 (2007) 735-748
29. Bueno L., de Ponti F., Fried M., Kullak-Ublick G.A., Kwiatek M.A., Pohl D., et al. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol Motil 19 1 Suppl (2007) 89-119
30. Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13 (2007) 35-37
31. Corr S.C., Li Y., Riedel C.U., O'Toole P.W., Hill C., and Gahan C.G. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 104 (2007) 7617-7621
32. Cotter P.D., O'Connor P.M., Draper L.A., Lawton E.M., Deegan L.H., Hill C., et al. Posttranslational conversion of l-serines to d-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147. Proc Natl Acad Sci USA 102 (2005) 18584-18589
33. Ait-Belgnaoui A., Han W., Lamine F., Eutamene H., Fioramonti J., Bueno L., et al. Lactobacillus farciminis treatment suppresses stress-induced visceral hypersensitivity: a possible action through interaction with epithelial cells cytoskeleton contraction. Gut 55 (2006) 1090-1094
34. Dunne C., Murphy L., Flynn S., O'Mahony L., O'Halloran S., Feeney M., et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 76 (1999) 279-292
35. McCarthy J., O'Mahony L., O'Callaghan L., Sheil B., Vaughan E.E., Fitzsimons N., et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52 (2003) 975-980
36. Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126 (2004) 520-528
37. Sheil B., McCarthy J., O'Mahony L., Bennett M.W., Ryan P., Fitzgibbon J.J., et al. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 53 (2004) 694-700
38. NASPGHAN Nutrition Report Committee, Michail S., Sylvester F., Fuchs G., and Issenman R. Clinical efficacy of probiotics: review of the evidence with focus on children. J Pediatr Gastroenterol Nutr 43 (2006) 550-557
39. Floch M.H., Walker W.A., Guandalini S., Hibberd P., Gorbach S., Surawicz C., et al. Recommendations for probiotic use-2008. J Clin Gastroenterol 42 Suppl. 2 (2008) S104-S108
40. Allen S.J., Okoko B., Martinez E., Gregorio G., and Dans L.F. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2 (2004) CD003048
41. D'Souza A.L., Rajkumar C.H., Cooke J., and Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhea: meta-analysis. BMJ 324 (2002) 1361-1366
42. Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., and Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67 (1999) 302-307
43. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101 (2006) 812-822
44. Ewaschuk J.B., Tejpar Q.Z., Soo I., Madsen K., and Fedorak R.N. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep 8 (2006) 486-498
45. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003) 1202-1209
46. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 (2004) 108-114
47. Hussein Z., and Quigley E.M. Complementary and alternative medicine in irritable bowel syndrome. Aliment Pharmacol Ther 15 (2006) 465-471
48. Quigley E.M.M., and Flourie B. Probiotics in irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19 (2007) 166-172
49. Nikfar S., Rahimi R., Rahimi F., Derakhshani S., and Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 51 (2008) 1775-1780
50. McFarland L.V., and Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14 (2008) 2650-2661
51. Hoveyda N., Heneghan C., Mahtani K.R., Perera R., Roberts N., and Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 9 (2009 Feb 16) 15
52. Moayyedi P., Ford A.C., Talley N.J., Cremonini F., Foxx-Orenstein A., Brandt L., and Quigley E. The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review. Gut (2008) December (Epublication ahead of print)
53. Brenner D.M., Moeller M.J., Chey W.D., and Schoenfeld P.S. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol (2009) March (Epublication ahead of print)
54. O'Mahony L., McCarthy J., Kelly P., Hurley, Luo F., Chen K., et al. A Randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology 128 (2005) 541-551
55. Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101 (2006) 326-333
56. Biarti B., and Matterelli P. The family Bifidobacteria. In: Dworkin M., Fallow S., Rosenberg E., Schieifer K.H., and Stackebrandt E. (Eds). The prokaryotes (2001), Springer, New York 1-70
57. Sen S., Mulan M.M., Parker T.J., Woolner J.T., Tarry G.A., and Hunter J.O. Effect of Lactobacillus plantarum 299 V on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 47 (2002) 2615-2620
58. Barrett J.S., Canale K.E., Gearry R.B., Irving P.M., and Gibson P.R. Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome. World J Gastroenterol 14 (2008) 5020-5024
59. Agrawal A., Houghton L.A., Morris J., Reilly B., Guyonnet D., Goupil Feuillerat N., Schlumberger A., Jakob S., and Whorwell P.J. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2008) September (Epublication ahead of print)
60. Wall R., Ross R.P., Shanahan F., O'Mahony L., O'Mahony C., Coakley M., et al. Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr 89 (2009) 1393-1401
61. Ley R.E. Obesity and the human microbiome. Curr Opin Gastroenterol 26 (2010) 5-11
62. Boyle R.J., Robins-Browne R.M., and Tang M.L.K. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 83 (2006) 1256-1264
63. Kunz A.N., Noel J.M., and Fairchok M.P. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 38 (2004) 457-458
64. DeGroote M.A., Frank D.N., Dowell E., Glode M.P., and Pace N.R. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 24 (2005) 278-280
65. Besselink M.G., van Santvoort H.C., Buskens E., Boermeester M.A., van Goor H., Timmerman H.M., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 651-659
66. EFSA Scientific Colloquium Summary Report. QPS qualified presumption of safety of micro-organisms in food and feed (2004), EFSA, Brussels
67. Depeint F., Tzprtzis G., Vulevic J., L'anson K., and Gibson G.R. Prebiotic evaluation of a novel galactooligosaccheride mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 44171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr 87 (2008) 785-791
68. Vos A.P., M'Rabert L., Stahl B., Boehm G., and Garssen J. Immunomodulatory effects and potential working mechanisms of orally applied nondigestible carbohydrates. Crit Rev Immunol 27 (2007) 97-140
69. Silk D.B.A., Davis A., Vulevic J., Tzortzis G., and Gibson G.R. Clinical trial: the effects of a trans-galactooligosaccheride on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29 (2009) 508-518
70. Bouhnik Y., Neut C., Raskine L., Michel C., Riottot M., Andrieux C., et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther 19 (2004) 889-899
71. Andriulli A., Neri M., Loguercio C., Terreni N., Merla A., Cardarella M.P., et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol 42 Suppl. 3 Pt 2 (2008) S218-S223
72. Colecchia A., Vestito A., La Rocca A., Pasqui F., Nikiforaki A., Festi D., and Symbiotic Study Group. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 52 (2006) 349-358
73. Tsuchiya J., Barreto R., Okura R., Kawakita S., Fesce E., and Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 5 (2004) 169-174
74. Dughera L., Elia C., Navino M., Cisarò F., and ARMONIA Study Group. Effects of symbiotic preparations on constipated irritable bowel syndrome symptoms. Acta Biomed 78 (2007) 111-116
75. Quigley E.M.M. The future of probiotics. In: Michail S., and Sherman P. (Eds). Probiotics in pediatric medicine (2008), Humana Press, Totowa, NJ 323-329